🇨🇳 TQB2102（双特异性 HER2 TOPO1 ADC）在以 HR+/HER2 低表达 MBC 为主的患者中也通过了“卡车测试”。PFS 16.4 对比 5.5 个月，HR 0.29，p<0.01。双特异性设计是否增加疗效尚不清楚。HER2 TOPO1 领域正变得相当拥挤，涌现出多款优秀药物。#ESMOAmbassadors #ESMO26
1671 浏览 · 21 赞 · 9 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：Paolo Tarantino · x.com